GP30101 + Prezista® + GP30101 + Prezista®
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
15
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Bioequivalence
Conditions
Bioequivalence
Trial Timeline
Jun 6, 2019 → Sep 6, 2019
NCT ID
NCT04268472About GP30101 + Prezista® + GP30101 + Prezista®
GP30101 + Prezista® + GP30101 + Prezista® is a pre-clinical stage product being developed by GEROPHARM for Bioequivalence. The current trial status is completed. This product is registered under clinical trial identifier NCT04268472. Target conditions include Bioequivalence.
Hype Score Breakdown
Clinical
5
Activity
2
Company
2
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04268472 | Pre-clinical | Completed |
Competing Products
20 competing products in Bioequivalence